Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA

April 30, 2021 By Cade Hildreth, Founder & President Leave a Comment

April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.

The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]

Horizon 2020 consortium funding to fuel cell therapy microcarrier development at denovoMATRIX

April 29, 2021 By Cade Hildreth, Founder & President Leave a Comment

DRESDEN, Germany, April 29, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced today that it will participate in the new European collaborative project funded by the European Union’s Horizon 2020 research and innovation program.

[Read more…]

Organicell Announces Positive Results Of Initial COVID-19 Zofin™ Patient Trial In India And Trial Expansion

April 28, 2021 By Cade Hildreth, Founder & President Leave a Comment

Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]

Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury

April 27, 2021 By Cade Hildreth, Founder & President Leave a Comment

A groundbreaking study from Neobiosis, a global expert in regenerative medicine, explains how a never-before-described process may open the door to regenerating damaged hearts. A peer-reviewed research paper from Dr. Ian White published in the journal Stem Cells and Regenerative Medicine explains how his studies of mouse hearts could be used to defeat a disease that kills 650,000 Americans each year.

ALACHUA, FLA., APRIL 21, 2021 – Cardiovascular disease kills more than 650,000 Americans annually.(1) Those who survive myocardial infarction remain at risk of death because the human heart has a very limited ability to repair itself. No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart. But all that may change thanks to a revolutionary medical paper written by Dr. Ian White, President and CSO of Neobiosis, a company that focuses on the science of regenerative medicine.

[Read more…]

Organicell Completes Enrollment For Its Expanded Access Trial To Treat COVID-19 Patients With Zofin™

April 22, 2021 By Cade Hildreth, Founder & President Leave a Comment

Miami, FL (April 22, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (FDA) granted expanded access trial for Zofin for the treatment of COVID-19. [Read more…]